ArticleJournal of neuro-oncology2025
Premature mortality due to malignancies of the central nervous system in Japan: a nationwide descriptive analysis from 2000 to 2020.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe applied the average lifespan shortened (ALSS) measure to examine lifespan's changes among individuals who died from malignancies of the central nervous system (CNS) in Japan from 2000 to 2020.
methodsMortality data due to CNS cancers were obtained from the World Health Organization Mortality Database. Years of life lost (YLL) were calculated using Japanese life tables. ALSS was calculated as the ratio between YLL and the expected lifespan, and its 95% confidence interval (95% CI) was calculated using the bootstrap method.
resultsOver the study, the age-standardized mortality rates adjusted to the World Standard Population due to CNS cancers increased from 1.0 to 1.3 deaths per 100,000 men and from 0.7 to 0.9 deaths per 100,000 women. ALSS results indicated that men with CNS malignancies lost 30.7% (95% CI: 29.2-32.2) of their lifespan in 2000, and 24.3% (95% CI: 23.4-25.3) in 2020. Similarly, ALSS values for women decreased from 32.9% (95% CI: 31.3-34.5) to 25.2% (95% CI: 24.1-26.3) over the same period.
conclusionOur study revealed a gain in lifespan of individuals with CNS cancers in both sexes in Japan over the 20-year period.
Indexed as
Identifiers
41091250What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.